Inhibitory Interneuron Cell Therapy Reduces Seizures in First 2 Patients With MTLE
Data from a phase 1/2 clinical trial of NRTX-1001 were presented at the ISSCR 2023 Annual Meeting.
Point-of-Care CAR T-Cell Therapy Yields 100% ORR in R/R CLL With or Without Richter’s Transformation
The phase 1/2 Euplagia-1 trial is currently ongoing in Europe.
2 Clarke Drive Cranbury, NJ 08512